Skip to main content
NIH funding notice PAR-19-339

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)

Closed on June 8, 2022.

Posted
August 12, 2019
Close date
June 8, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $183,494 in first-year total cost, median $183,494.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 BDCN-Q (55)]1

Most frequent institutions

  1. RUTGERS THE STATE UNIV OF NJ NEWARK1
Competing awards under PAR-19-339 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Candidate mechanisms for chemotherapy-induced neurocognitive deficits in pediatric solid non-CNS tumor patients1R21CA262491-01BAKER, TRAVIS E.RUTGERS THE STATE UNIV OF NJ NEWARK, NJ$183,494ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.